. 2022 Nov 14;23:481. doi: 10.1186/s12859-022-05005-1

Table 1.

Summary of datasets used

Dataset	Samples	Sample source	Assay	Number of metabolites mapping to ChEBI	Number of Reactome pathways accessible^a
Su et al. [38]	COVID19 (n = 130), Non-COVID19 (n = 133)	Blood plasma	UHPLC/MS/MS (Metabolon)	335	255
Lloyd-Price et al. [39]	CD (n = 265), UC (n = 146), Non-IBD (n = 135)	Stool	LC–MS HILIC-pos, LC–MS HILIC-neg, LC–MS C18-neg, LC–MS C8-pos	329	228

Dataset

Samples

Sample source

Assay

Number of metabolites mapping to ChEBI

Number of Reactome pathways accessible^a

Su et al. [38]

COVID19

(n = 130),

Non-COVID19

(n = 133)

Blood plasma

UHPLC/MS/MS (Metabolon)

335

255

Lloyd-Price et al. [39]

CD (n = 265),

UC (n = 146),

Non-IBD

(n = 135)

Stool

LC–MS HILIC-pos, LC–MS HILIC-neg, LC–MS C18-neg, LC–MS C8-pos

329

228

^aNumber of Reactome pathways accessible corresponds to the number of pathways in each dataset which contained at least two metabolites assayed in the metabolomics data